Avanos Medical (AVNS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Avanos Medical

NYSE•Healthcare•Medical Devices

$24.99+0.01(<0.01%)Market open

Market Cap

$1.16B

P/S

1.6x

P/B

1.5x

Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; and Trident and Esentec RFA radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. Avanos Medical, Inc. was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. The company was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

How this company scores

AverageMetricSide Score: 56/100

Strongest: Balance Sheet & Red Flags (21/25); weakest: Cash & Earnings Quality (6/25).

Profitability13/25

Growth16/25

Balance Sheet & Red Flags21/25

Cash & Earnings Quality6/25

Strengths

Low leverageProfit converts from growthConsistent growthImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 73.2x5y range 23.0x – 500.8x

Currently near its 8-quarter median.

P/S · 1.6x5y range 1.4x – 1.8x

Currently near its 20-quarter median.

P/B · 1.5x5y range 0.9x – 1.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

FCF consistently trails net income (avg -0.6x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $1.16B

Metrics at a Glance

as of March 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $715.90M
Q. Revenue: $182.20M
TTM EBITDA: $-23.50M
TTM Op. Income: $-63.00M
Q. Op. Income: $8.90M
TTM Net Income: $-74.40M
Q. Net Income: $5.10M
EPS: $0.11
Shares Out.: $46.50M

$715.90M in TTM revenue grew 3.9% YoY, reaching $182.20M last quarter. TTM EBITDA of $-23.50M and TTM operating income of $-63.00M show growth is flowing through to the bottom line. However, net income is negative at $74.40M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 51.7%
EBITDA Margin: 10.5%
Op. Margin: 4.9%
Net Margin: 2.8%

Op. margin of 4.9% is down 1.3% YoY — costs are rising relative to revenue. Net margin at 2.8% and gross margin of 51.7% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 3 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.6x
P/B Ratio: 1.5x

P/S of 1.6x and P/B of 1.5x. P/S is low relative to typical market levels. Over the past year, P/E is up 0% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.05B
Cash: $65.60M
Long-Term Debt: $87.30M
Book Value: $782.10M
D/E Ratio: 0.1
Debt/EBITDA: 4.6

With $1.05B in assets and $87.30M in long-term debt, D/E is 0.1and book value is $782.10M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-12.30M
TTM Free Cash Flow: $7.50M
FCF Margin: 1.0%
FCF / Net Income: -0.1

TTM FCF of $7.50M on $-12.30M in operating cash flow. The FCF / Net Income ratio of -0.1x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has fallen for 4 consecutive quarters — a weakening trend.